Latest news with #Baral
Business Insider
20 hours ago
- Business
- Business Insider
TD Cowen Remains a Hold on Spero Therapeutics (SPRO)
TD Cowen analyst Ritu Baral maintained a Hold rating on Spero Therapeutics (SPRO – Research Report) today. The company's shares closed today at $2.85. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Baral covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Vera Therapeutics. According to TipRanks, Baral has an average return of 7.1% and a 47.08% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Spero Therapeutics.
Business Insider
19-05-2025
- Business
- Business Insider
TD Cowen Reaffirms Their Hold Rating on Spero Therapeutics (SPRO)
TD Cowen analyst Ritu Baral maintained a Hold rating on Spero Therapeutics (SPRO – Research Report) yesterday. The company's shares closed last Friday at $0.65. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Baral is a 3-star analyst with an average return of 2.5% and a 39.31% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Spero Therapeutics. SPRO market cap is currently $36.4M and has a P/E ratio of -0.51.
Business Insider
19-05-2025
- Business
- Business Insider
TD Cowen Sticks to Their Hold Rating for Milestone Pharmaceuticals (MIST)
TD Cowen analyst Ritu Baral maintained a Hold rating on Milestone Pharmaceuticals (MIST – Research Report) yesterday. The company's shares closed last Friday at $1.22. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Baral is a 3-star analyst with an average return of 2.5% and a 39.31% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Madrigal Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Milestone Pharmaceuticals with a $7.50 average price target. MIST market cap is currently $65.23M and has a P/E ratio of -1.47.
Business Insider
29-04-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (OtherTLPPF) and Alnylam Pharma (ALNY)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Telix Pharmaceuticals (TLPPF – Research Report) and Alnylam Pharma (ALNY – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Telix Pharmaceuticals (TLPPF) Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. The company's shares closed last Monday at $17.00. According to Hester is a 4-star analyst with an average return of 4.8% and a 50.6% success rate. Hester covers the Healthcare sector, focusing on stocks such as Paradigm Biopharmaceuticals, Pro Medicus Limited, and Nanosonics Limited. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Telix Pharmaceuticals with a $21.88 average price target, representing a 28.7% upside. In a report issued on April 22, TD Cowen also maintained a Buy rating on the stock with a A$35.00 price target. Alnylam Pharma (ALNY) TD Cowen analyst Ritu Baral maintained a Buy rating on Alnylam Pharma today and set a price target of $371.00. The company's shares closed last Monday at $254.85. According to Baral is a 3-star analyst with an average return of 2.0% and a 39.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Milestone Pharmaceuticals, and Sionna Therapeutics, Inc. Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $312.95, a 23.8% upside from current levels. In a report issued on April 15, Evercore ISI also maintained a Buy rating on the stock with a $280.00 price target.
